MedDataX Logo

Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)

NCT ID: NCT03184363

Last Updated: 2017-06-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines

NCT02882893

Crows Feet Lines
UNKNOWN PHASE2/PHASE3

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

NCT01629875

Moderate to Severe Glabellar Line
COMPLETED PHASE3

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

NCT06212960

Glabellar Lines
COMPLETED PHASE1

A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet

NCT04818203

Crow's Feet
RECRUITING PHASE1/PHASE2

Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

NCT07013279

Glabellar Lines
NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crow's Feet Lines Glabellar Lines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clostridium Botulinum A Toxin

Clostridium Botulinum A Toxin

Group Type EXPERIMENTAL

Clostridium Botulinum A Toxin

Intervention Type DRUG

Clostridium Botulinum A Toxin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clostridium Botulinum A Toxin

Clostridium Botulinum A Toxin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female of at least 18 to 75 years old
* moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
* moderate-to-severe GL at maximum frawn on the FWS as rated by the investigator
* Subject who has completed phase 3 study for CFL.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DW_DWP450005E

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BOTOX® in the Treatment of Crow's Feet Lines in China
NCT02195687 COMPLETED PHASE3
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
NCT02568150 COMPLETED PHASE4
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01940991 COMPLETED PHASE2
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
NCT02677298 COMPLETED PHASE3
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
NCT04225260 COMPLETED PHASE3
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
NCT05463965 COMPLETED PHASE3
Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines
NCT03408236 COMPLETED PHASE3
A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
NCT01308060 COMPLETED PHASE3
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
NCT01391312 COMPLETED PHASE4
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01776606 COMPLETED PHASE3
Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study
NCT01529788 COMPLETED PHASE4
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
NCT05804656 COMPLETED PHASE3
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
NCT04081402 UNKNOWN PHASE3
A Prospective, Multicenter, Blind, Randomized Controlled, Optimal Clinical Trial to Evaluate the Safety and Efficacy of Medical Collagen Fillers for Facial Dermal Tissue Filling to Correct Frontal Wrinkles (crow's Feet)
NCT06703294 NOT_YET_RECRUITING PHASE3
Sculptra for Décolletage Crepiness and Wrinkling
NCT03508973 COMPLETED NA
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
NCT05292638 COMPLETED PHASE1
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
NCT01358695 COMPLETED PHASE2
Open Label Study Exploring Tissue Histopathology After Ellacor® Procedure in an Abdominoplasty Model.
NCT06421207 COMPLETED NA
Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01818076 TERMINATED PHASE3
Perception of Facial Expression in Subjects With and Without Crow's Feet Lines
NCT02417077 COMPLETED
Treatment of Moderate to Severe Glabellar Lines
NCT04249583 COMPLETED PHASE3
Subject Satisfaction With AbobutulinumtoxinA Treatment
NCT03687736 COMPLETED PHASE4
Healing Study of Fractional Skin Resurfacing and Tissue Histopathology After Ellacor Treatment
NCT06502470 COMPLETED NA
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
NCT04157686 COMPLETED PHASE3
Radio Frequency Microneedling for Suprapatellar Skin
NCT03507036 COMPLETED NA